Harvard Bioscience price target lowered to $3 from $4.50 at Benchmark
Benchmark lowered the firm’s price target on Harvard Bioscience (HBIO) to $3 from $4.50 and keeps a Speculative Buy rating on the shares. The outlook for end-user markets in biomedical research continues to be challenging due to uncertainty around China …